Gland Pharma receives USFDA’s tentative approval for Cangrelor for Injection

08 Dec 2021 Evaluate

Gland Pharma has received a tentative approval from the United States Food and Drug Administration (USFDA) for Cangrelor for Injection, 50 mg/vial Single-Dose Vials. The company is amongst one of the first to files for this product and may be eligible for 180 days of generic drug exclusivity. The company will launch the product with its marketing partner on receipt of final approval.

Gland Pharma develops, manufactures and markets complex injectables. The company sells its products primarily under a business-to-business model in over 60 countries, including the US, Canada, Australia and India.

Gland Pharma Share Price

1750.55 19.70 (1.14%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×